Julie Lurie
Acute Care · Cincinnati, OHNPI 1447571534
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,407 of the $13,104 with a category attached, or 79.4%. 28 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 27.7% of the total. 2025 is the largest year on record at $4,265, 3.0 times the $1,402 reported in 2021. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 490 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$4K
- AstraZeneca$2K
- ZOLL Respicardia, Inc.$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$865
- Grifols USA, LLC$652
- plus $3K from 22 others
What the payments were for
- Travel & lodging$2,52219%
- Food & beverage$10,40779%
- Education$1751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 75 | $3,635 |
| AstraZeneca | 72 | $1,735 |
| ZOLL Respicardia, Inc. | 2 | $1,473 |
| GSK | 100 | $1,423 |
| Regeneron Healthcare Solutions, Inc. | 39 | $865 |
| Grifols USA, LLC | 34 | $652 |
| Sanofi | 31 | $612 |
| Boehringer Ingelheim | 24 | $517 |
| Amgen | 16 | $306 |
| Axsome Therapeutics, Inc. | 13 | $240 |
| Genentech USA, Inc. | 11 | $224 |
| United Therapeutics Corporation | 10 | $219 |
| Actelion Pharmaceuticals US, Inc. | 10 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| Insmed, Inc. | 6 | $136 |
| Merck | 7 | $129 |
| Mylan Specialty L.p. | 6 | $109 |
| Jazz Pharmaceuticals Inc. | 6 | $105 |
| Gilead | 3 | $54 |
| Pulmonx Corporation | 2 | $46 |
| Kaleo, Inc. | 3 | $46 |
| Baxter Healthcare | 2 | $41 |
| Verona Pharma, Inc. | 2 | $39 |
| Bayer | 2 | $33 |
| Novartis | 2 | $32 |
| Viatris Specialty LLC | 2 | $30 |
| Lilly USA, LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,104 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 204 | $234,817 |
| OfevNintedanib Esylate | 15 | $146,067 |
| Dupixent PenDupilumab | 15 | $54,249 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $36,933 |
| Spiriva RespimatTiotropium Bromide | 23 | $34,853 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $20,396 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $20,239 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $11,780 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $2,692 |
| Zolpidem Tartrate ErZolpidem Tartrate | 18 | $403 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $379 |
| Azithromycin | 18 | $322 |
| Paroxetine Hcl | 21 | $255 |
| Eszopiclone | 12 | $222 |
| Prednisone | 41 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,423 | $292,146272 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $517 | $180,92038 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,735 | $32,01935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Cincinnati
- Laura LangenhopCincinnati$8K
- Jennifer ClarkCincinnati$7K
- Amy HawkinsCincinnati$7K
- Rebecca BlantonCincinnati$6K
- Carrie MyersCincinnati$6K
- Kathleen RoederCincinnati$6K
- Nicole BrownCincinnati$5K
- Donna AbdelnourCincinnati$5K
- Bonnie AlbertCincinnati$4K
- Jessica HendrixCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.